Cargando…

Proactive measurement of infliximab drug levels in children with Crohn’s disease

BACKGROUND: Proactively monitoring infliximab levels is an emerging area of interest in pediatric Crohn’s disease. There are only limited data on therapeutic drug monitoring for children with Crohn’s disease. The goal of our study was to determine the utility of therapeutic drug monitoring in achiev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holland, Kathleen, Bennett, William E., Slaven, James E., Collier, John, Waltz, Gail, Pfefferkorn, Marian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hellenic Society of Gastroenterology 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713342/ https://www.ncbi.nlm.nih.gov/pubmed/34987289 http://dx.doi.org/10.20524/aog.2021.0676

Ejemplares similares

Prospective randomised controlled trial of adults with perianal fistulising Crohn’s disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol
por: Gu, Bonita, et al.
Publicado: (2021)

Real-World Experience With Proactive Therapeutic Drug Monitoring During Infliximab Reintroduction
por: Normatov, Inessa, et al.
Publicado: (2021)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease
por: Gomes, Luis Eduardo Miani, et al.
Publicado: (2019)

Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Infliximab for medical induction of remission in Crohn's disease
por: Gordon, Morris, et al.
Publicado: (2023)

Infliximab to treat Crohn’s disease: an update
por: Cottone, M, et al.
Publicado: (2011)

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab
por: Sorrentino, Dario, et al.
Publicado: (2015)

Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease
por: Gouldthorpe, Oliver, et al.
Publicado: (2013)

Management Decisions in Crohn’s Disease Are Changed by Knowledge of Proactive and Reactive Testing of Antitumor Necrosis Factor Drug Levels
por: Wu, Yang, et al.
Publicado: (2021)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Metastatic Crohn’s disease despite infliximab therapy
por: Campos, Sara, et al.
Publicado: (2017)

Myelolipoma After Infliximab Treatment for Crohn's Disease
por: Cesa, Kevin, et al.
Publicado: (2022)

The New Proactive Approach and Precision Medicine in Crohn’s Disease
por: Zittan, Eran, et al.
Publicado: (2020)

Changes in the Intestinal Microbiota Are Seen Following Treatment with Infliximab in Children with Crohn’s Disease
por: Kowalska-Duplaga, Kinga, et al.
Publicado: (2020)

Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy
por: Cao, Wan-Ting, et al.
Publicado: (2022)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
por: Choi, So Yoon, et al.
Publicado: (2023)

Vaccination Rates and Family Barriers Among Children with Inflammatory Bowel Disease
por: Holland, Kathleen J, et al.
Publicado: (2020)

Infliximab therapy in pediatric Crohn’s disease: a review
por: Parashette, Kalyan Ray, et al.
Publicado: (2010)

Maintenance treatment with infliximab for the management of Crohn’s disease in adults
por: Caviglia, Renato, et al.
Publicado: (2009)

Infliximab-induced intertriginous psoriasis in patient with Crohn's disease
por: Mola, Federica, et al.
Publicado: (2011)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
por: Kim, You Lim, et al.
Publicado: (2014)

Infliximab in the Treatment of Crohn Disease and Type 1 Diabetes
por: Timper, Katharina, et al.
Publicado: (2013)

Efficacy of Infliximab for the Treatment of Oral Manifestation of Crohn’s Disease
por: Aginbay, Aibar, et al.
Publicado: (2022)

Proactive Drug Monitoring Is Associated With Higher Persistence to Infliximab and Adalimumab Treatment and Lower Healthcare Utilization Compared With Reactive and Clinical Monitoring
por: Syed, Nauroz, et al.
Publicado: (2020)

Effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in Crohn’s disease
por: Carter, Chureen T, et al.
Publicado: (2012)

Infliximab-Induced Aseptic Meningitis in a Patient with Crohn’s Disease
por: Junga, Zachary, et al.
Publicado: (2018)

Early intestinal obstruction after infliximab therapy in Crohn’s disease
por: Chiba, Mitsuro, et al.
Publicado: (2019)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Optimized timing of using infliximab in perianal fistulizing Crohn's disease
por: Sun, Xue-Liang, et al.
Publicado: (2020)

Gummatous cutaneous tuberculosis associated with the use of infliximab for Crohn's disease()()
por: Garcia, Lucas Campos, et al.
Publicado: (2021)

Cortical Vein Thrombosis after Infliximab Treatment for Crohn’s Disease
por: Razmeh, Saeed, et al.
Publicado: (2021)

Brain Abscesses in Crohn’s Disease as a Complication of Infliximab Therapy
por: Mansour, Mahmoud M, et al.
Publicado: (2021)

The impact of medication belief on adherence to infliximab in patients with Crohn’s disease
por: Li, Shuyan, et al.
Publicado: (2023)

Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn’s Disease
por: Orts, Beatriz, et al.
Publicado: (2022)

Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease
por: de Bruyn, Jessica R., et al.
Publicado: (2018)

Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab
por: Park, Jihye, et al.
Publicado: (2023)

A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn’s Disease
por: Hughes, Avery, et al.
Publicado: (2020)

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
por: Lichtenstein, Gary R, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5nnp19k77090t0j137dbc8dku2